Title: Advances in Gene Therapy – 2024 Update

Sponsored by The Therapeutics Committee 

Date of Release: July 2, 20024
Expiration Date:  July 2, 20026

Credits offered: CME

Estimate time of completion: 1 hour per webinar

Course must be completed by the expiration date

www.acmgeducation.net

Description:

Access our on-demand webinar, a follow-up to the 2022 Summer Gene Therapy Webinar, featuring essential updates and in-depth insights on groundbreaking advancements in gene therapy. Stay up to date on cutting-edge innovations shaping the future of genetic medicine.

Target Audience: This webinar is designed for trainees, medical geneticists, biochemical geneticists,

neurologists, and laboratory geneticists who are eager to stay at the forefront of gene therapy advancements.

Learning Objectives

At the conclusion of this session, participants should be able to:

1. Expand Knowledge on CRISPR and Gene Replacement Therapy: Provide comprehensive updates on the latest developments in CRISPR technology and gene replacement therapy, focusing on how these innovations are shaping the future of genetic medicine.
2.  
3. Review New Pediatric Neurogenetic Therapies: Examine recently approved gene therapies for pediatric neurogenetic conditions such as Metachromatic Leukodystrophy (MLD), Duchenne Muscular Dystrophy (DMD), and X-linked Adrenoleukodystrophy (XALD). Discuss their clinical applications, efficacy, and impact on patient outcomes.
4. Discuss Gene Therapy for Sickle Cell Disease: Delve into the specifics of gene therapy for sickle cell disease, exploring the underlying mechanisms and therapeutic potential. Highlight case studies and clinical trial results to illustrate the transformative effects of these treatments.
5.  
6. Analyze Financial and Ethical Considerations: Address the economic aspects and ethical implications of gene therapy. Evaluate the cost-effectiveness, accessibility, and ethical challenges associated with these advanced therapies to foster informed decision-making among healthcare professionals and patients.

CME AMA PRA Category 1 ^TM

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country. Non-physicians may request a certificate of attendance for their participation.

Claiming your Educational Credits

This activity consists of: View content, take a post-test, the test may be taken as often as necessary to achieve a passing score of 80% or better is required to receive credit.  If you do not achieve a passing score, the program will identify which questions you answered incorrectly so that you can review the module and try again. Complete the evaluation form.

Learner Data Consent

ACMG Education reports learner data to respective agency boards and you will be asked for consent during the evaluation process. Your compliance with deadlines and completing evaluations are part of the process in meeting learner needs and ACMG’s education mission.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to the improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

• Financial Disclosures and Mitigation Procedure
• ACMG Content Validation Policy
• ACMG Content Branding Policy

All of the relevant financial relationships listed for these individuals have been mitigated.